drugset / Trial / NCT00005764

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

NCT00005764

Phase 4 Completed 100 enrolled Glaxo Wellcome
Treatment

Summary

The purpose of this study is to see if the findings of increased lactic acid and abnormal fat distribution get better when d4T is replaced with abacavir, abacavir plus lamivudine, or Combivir (a pill containing lamivudine plus zidovudine) in HIV-positive patients taking anti-HIV therapy including stavudine (d4T).

Timeline

Start
2000-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified
Subject Lamivudine Other / unclassified
Subject Zidovudine Small molecule